Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen.

Next Previous
Trial Profile

A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms GRANITE-2; RADPAC

Most Recent Events

  • 27 Jan 2020 Status changed from active, no longer recruiting to completed.
  • 16 Aug 2019 Planned End Date changed from 1 Apr 2019 to 1 Aug 2019.
  • 07 Mar 2019 Planned End Date changed from 1 Aug 2018 to 1 Apr 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top